1. J Clin Exp Hematop. 2012;52(2):145-7. doi: 10.3960/jslrt.52.145.

Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with 
dasatinib therapy in a patient with imatinib-resistant chronic myelogenous 
leukemia.

Inokuchi K, Yamaguchi H, Tamai H, Dan K.

DOI: 10.3960/jslrt.52.145
PMID: 23037633 [Indexed for MEDLINE]